46. Malignant rheumatoid arthritis
4,183 clinical trials,   2,538 drugs   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-021283-14-IT
(EUCTR)
01/02/201123/12/2010A randomised, double blind, placebo-controlled, multiple dose trial of NNC109-0012 (Anti-IL-20) in subjects with rheumatoid arthritis - NN8226-3875A randomised, double blind, placebo-controlled, multiple dose trial of NNC109-0012 (Anti-IL-20) in subjects with rheumatoid arthritis - NN8226-3875 Rheumatoid arthritis
MedDRA version: 9.1;Level: LLT;Classification code 10039073
Product Name: Anti-IL-20 (109-0012)
Product Code: NNC 0109-0000-0012
NOVO NORDISKNULLNot RecruitingFemale: yes
Male: yes
66Hungary;Portugal;United Kingdom;Spain;Italy
2NCT01282255
(ClinicalTrials.gov)
February 201121/1/2011Efficacy of NNC109-0012 in Subjects With Active Rheumatoid ArthritisA Randomised, Double Blind, Placebo-controlled, Multiple Dose Trial of Anti-IL-20 (109-0012) in Subjects With Rheumatoid ArthritisInflammation;Rheumatoid ArthritisDrug: NNC109-0012;Drug: placeboNovo Nordisk A/SNULLCompleted18 Years75 YearsAll67Phase 2Czech Republic;Germany;Italy;Poland;Portugal;Romania;Spain;United Kingdom